Unknown

Dataset Information

0

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression.


ABSTRACT:

SUBMITTER: Foldi J 

PROVIDER: S-EPMC10316092 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression.

Foldi Julia J   Brufsky Adam A  

Annals of translational medicine 20230407 9


Similar Datasets

| S-EPMC6111440 | biostudies-literature
| S-EPMC7796879 | biostudies-literature
| S-EPMC1187955 | biostudies-literature
| S-EPMC10655667 | biostudies-literature
| S-EPMC3778871 | biostudies-literature
| S-EPMC5477652 | biostudies-literature
| S-EPMC8773807 | biostudies-literature
| S-EPMC4613943 | biostudies-literature
| S-EPMC3798538 | biostudies-literature
| S-EPMC3689728 | biostudies-literature